drugset / Trial / NCT01085656
A Phase I Clinical Trial of OXi4503 for Relapsed and Refractory AML and MDS
NaSingle-groupOpen-labelTreatment
Summary
This study is intended to determine the safety and maximum tolerated dose of a drug, OXi4503 (combretastatin A1 diphosphate, CA1P, OXiGENE), in patients with relapsed and refractory AML and MDS.
Timeline
- Start
- 2011-02
- Primary completion
- 2016-01
- Completion
- 2016-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | OXi4503 | Other / unclassified | 2.5 mg/m2 | Intravenous |
| Subject | OXi4503 | Other / unclassified | 3.75 mg/m2 | Intravenous |
| Subject | OXi4503 | Other / unclassified | 5 mg/m2 | Intravenous |